Literature DB >> 28009422

Position paper of the Italian Association of Medical Oncology on early palliative care in oncology practice (Simultaneous Care).

Vittorina Zagonel1, Vittorio Franciosi2, Antonella Brunello1, Guido Biasco3, Chiara Broglia4, Daniela Cattaneo5, Luigi Cavanna6, Domenico Corsi7, Gabriella Farina8, Luisa Fioretto9, Teresa Gamucci10, Gaetano Lanzetta11, Roberto Magarotto12, Marco Maltoni13, Paolo Marchetti14, Elena Massa15, Cataldo Mastromauro16, Barbara Melotti17, Fausto Meriggi18, Angelo Nacci19, Ida Pavese20, Erico Piva21, Michela Quirino22, Mario Roselli23, Cosimo Sacco24, Giuseppe Tonini25, Leonardo Trentin26, Giovanni Ucci27, Roberto Labianca28, Stefania Gori12, Carmine Pinto29, Stefano Cascinu30.   

Abstract

One of the priorities of personalized medicine regards the role of early integration of palliative care with cancer-directed treatments, called simultaneous care. This article, written by the Italian Association of Medical Oncology (AIOM) Simultaneous and Continuous Care Task Force, represents the position of Italian medical oncologists about simultaneous care, and is the result of a 2-step project: a Web-based survey among medical oncologists and a consensus conference. We present the opinion of more than 600 oncologists who helped formulate these recommendations. This document covers 4 main aspects of simultaneous care: 1) ethical, cultural, and relational aspects of cancer and implications for patient communication; 2) training of medical oncologists in palliative medicine; 3) research on the integration between cancer treatments and palliative care; and 4) organizational and management models for the realization of simultaneous care. The resulting recommendations highlight the role of skills and competence in palliative care along with implementation of adequate organizational models to accomplish simultaneous care, which is considered a high priority of AIOM in order to grant the best quality of life for cancer patients and their families.

Entities:  

Mesh:

Year:  2016        PMID: 28009422     DOI: 10.5301/tj.5000593

Source DB:  PubMed          Journal:  Tumori        ISSN: 0300-8916            Impact factor:   2.098


  5 in total

Review 1.  Standards, Guidelines, and Quality Measures for Successful Specialty Palliative Care Integration Into Oncology: Current Approaches and Future Directions.

Authors:  Arif H Kamal; Claudia Bausewein; David J Casarett; David C Currow; Deborah J Dudgeon; Irene J Higginson
Journal:  J Clin Oncol       Date:  2020-02-05       Impact factor: 44.544

2.  Simultaneous Care in Oncology: A 7-Year Experience at ESMO Designated Centre at Veneto Institute of Oncology, Italy.

Authors:  Antonella Brunello; Antonella Galiano; Stefania Schiavon; Mariateresa Nardi; Alessandra Feltrin; Ardi Pambuku; Chiara De Toni; Alice Dal Col; Evelina Lamberti; Chiara Pittarello; Francesca Bergamo; Umberto Basso; Marco Maruzzo; Silvia Finotto; Maital Bolshinsky; Silvia Stragliotto; Letizia Procaccio; Mario Domenico Rizzato; Fabio Formaglio; Giuseppe Lombardi; Sara Lonardi; Vittorina Zagonel
Journal:  Cancers (Basel)       Date:  2022-05-23       Impact factor: 6.575

Review 3.  Can early palliative care with anticancer treatment improve overall survival and patient-related outcomes in advanced lung cancer patients? A review of the literature.

Authors:  Massimo Ambroggi; Claudia Biasini; Ilaria Toscani; Elena Orlandi; Raffaella Berte; Martina Mazzari; Luigi Cavanna
Journal:  Support Care Cancer       Date:  2018-04-27       Impact factor: 3.603

Review 4.  The Role of Nutritional Support for Cancer Patients in Palliative Care.

Authors:  Paolo Cotogni; Silvia Stragliotto; Marta Ossola; Alessandro Collo; Sergio Riso
Journal:  Nutrients       Date:  2021-01-22       Impact factor: 5.717

5.  Prognostication in palliative radiotherapy-ProPaRT: Accuracy of prognostic scores.

Authors:  Marco Maltoni; Emanuela Scarpi; Monia Dall'Agata; Simona Micheletti; Maria Caterina Pallotti; Martina Pieri; Marianna Ricci; Antonino Romeo; Maria Valentina Tenti; Luca Tontini; Romina Rossi
Journal:  Front Oncol       Date:  2022-08-16       Impact factor: 5.738

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.